secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2022-09-09T23:59:59+00:00
Accession:  0001558370-22-014299
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor appoints Nancy Valente to board; Yujiro Hata resigns
-----------------------------------------------------------

- Nancy Valente, M.D., appointed to Board on Sept 8, 2022; she brings 20+ yrs pharma experience.
- Yujiro Hata's resignation accepted by Board on Sept 8, 2022; he served since 2015.
- Valente receives initial option grant valued at $550k (Black-Scholes) plus $50k annual cash retainer.
- Valente most recently SVP at Genentech/Roche, led global oncology/hematology product development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000155837022014299/0001558370-22-014299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000155837022014299/xncr-20220909x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-014299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer